Ramucirumab, a fully IgG1 monoclonal antibody VEGF‐R2, has been evaluated in the second‐line setting, and did not affect survival in an unselected HCC population; improved outcomes were only evident among a poor prognosis alpha‐fetoprotein (AFP)‐high subgroup (≥400 ng/ml).7 Here, AFP is linked to hepatocellular carcinoma.